Navigation Links
New Intra-Arrest Cooling Method May Save More Brains During Cardiac Arrest

ORLANDO, Fla., Nov. 15 /PRNewswire/ -- The first randomized intra-arrest cooling study performed using a novel intra-nasal cooling method showed much faster and earlier cooling in treated patients and significantly higher neurologically intact survival - to - discharge rate in many patients. The Pre-Resuscitation Intra-Nasal Cooling Effectiveness (PRINCE) study involved 200 patients and was conducted by 15 Emergency Medical Systems (EMS) in Belgium, Germany, Italy, Czech Republic and Sweden. The aim was to determine safety and efficacy of intra-nasal cooling during ongoing resuscitation of cardiac arrest patients even before the return of circulation (ROSC).

The study was conducted using RhinoChill(TM), a non-invasive nasal catheter that sprays a rapidly evaporating coolant liquid into the nasal cavity. This large cavity is a heat exchanger and lies right under the brain.

The trial was designed to determine the safety and effectiveness of early cooling initiated at the site of the arrest. The RhinoChill(TM) technology enabled cooling to start much earlier than is possible with conventional methods used in a hospital setting and focuses on the brain. "The brain is the organ that dies first so the closer to the time of arrest the brain is cooled, the more of it is rescued," said Denise Barbut, M.D, founder and CEO of BeneChill, the company that makes RhinoChill. "The brain is the organ that controls the heart, much like a puppet on a string," she added.

Additional endpoints included cooling rates, time to achieve target temperature, ease of use in the field, ROSC rates, survival and neurologically intact survival. EMS personnel recruited adults over 18 years old who were in cardiac arrest and not hospitalized during resuscitation. All patients who were deemed eligible for advance cardiac life support (ACLS) were included as long as the arrest was witnessed and cardiopulmonary resuscitation (CPR) was initiated within 20 minutes of collapse.

The results of the study included:

  • Cooling was initiated 23 minutes following arrest and lowered brain temperature (tympanic) (34.2 degrees C vs. 35.5 degrees C) and body (core) temperature (35.1 degrees C vs. 35.8 degrees C) significantly by ER arrival.
  • Time to target tympanic temperature of 34 degrees was three hours faster and time to target core temperature was two hours faster in patients cooled intra-nasally in the field compared to those receiving hospital cooling alone.
  • Survival to discharge was higher in treated patients admitted to hospital (46.7% vs 31%) and significantly higher in those in whom CPR was initiated within 10 minutes of collapse, irrespective of rhythm (59.1% vs 29.4%).
  • Neurologically intact survival to discharge was higher in treated patients admitted to the hospital (36.7% vs 21.4%) and significantly higher in those in whom CPR was initiated within 10 minutes of collapse, irrespective of rhythm (45.5% vs 17.6%).
  • Intra-nasal cooling with RhinoChill was feasible and safe during an arrest. Nasal discoloration was the most commonly reported adverse event occurring in 13 patients. This resolved spontaneously in all patients who were successfully resuscitated.

Maaret Castren, M.D, Ph.D of the Department of Clinical Science and Education, Karolinska Institute, Stockholm, Sweden and the Department of Emergency Medicine, Sodersjukhuset and PRINCE lead investigator noted, "In this study, early cooling of the brain combined with early CPR favorably affected outcomes, irrespective of rhythm. We believe that this study demonstrates that making every attempt to initiate both CPR and intra-arrest cooling as early as possible in the resuscitation process should be adopted."

The EMS teams also noted that the portability of the device and ease of use meant that cooling could be administered in the field by non-specialized medical personnel. This also is useful in the hospital setting where the patient can be transported around with on-going cooling.

Dr. Castren presented the findings in Orlando, FL on Sunday, November 15 during the American Heart Association's Resuscitation Science Symposium "Best of the Best" presentations.

The sponsor of the study is BeneChill, a privately held medical device company which develops novel, rapid cooling systems to improve survival and brain function after cardiac arrest and other forms of brain ischemia. Its lead product, RhinoChill, which was used in the PRINCE study, can be administered quickly and close to the brain using a nasal catheter that delivers a rapidly evaporating coolant. RhinoChill will be marketed in Europe in early 2010 and currently is not available in the US.

SOURCE BeneChill

SOURCE BeneChill
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BeneChill Launches European Study of Intra-Arrest Cooling
2. Rapid Cooling Might Help Heart Attack Patients
3. Cooling May Reduce Brain Lesions in Newborns
4. Cooling Helps Oxygen-Deprived Newborns
5. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
6. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
7. Nationwide Heat Wave Finally Gives Way To Cooling Trend
8. Keep Safety in Mind While Cooling Off in the Water
9. Chill Cooling Towels Introduces Instant Relief for Hot Flashes and Night Sweats
10. St. Josephs Healthcare System Becomes First Hospital in the Region to Implement Pre-Hospital Therapeutic Cooling to Save the Lives of Cardiac Arrest Patients
11. Top Neurology Programs Control Fever with Arctic Sun Cooling Technology
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: